Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by Revolution Medicines, Inc. on June 8, 2023. The record date for the meeting was April 20, 2023, with 106,309,642 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
Stockholders voted on three proposals. The results were as follows:
- Proposal 1 (Election of Directors): Three Class III directors were elected.
- Mark A. Goldsmith, M.D., Ph.D.: 87,159,600 votes For; 2,352,047 votes Withheld.
- Barbara Weber, M.D.: 73,933,569 votes For; 15,578,078 votes Withheld.
- Alexis Borisy: 41,488,497 votes For; 48,023,150 votes Withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP.
- Votes For: 94,850,743
- Votes Against: 6,594
- Abstentions: 1,147
- Proposal 3 (Executive Compensation): Stockholders approved the advisory vote on executive compensation.
- Votes For: 88,731,273
- Votes Against: 773,142
- Abstentions: 7,232
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the significant number of votes withheld for director nominee Alexis Borisy (48,023,150) compared to votes for (41,488,497), indicating substantial stockholder dissent on this specific candidate.
- Confirm the total number of broker non-votes (5,346,837) which impacted the director election and executive compensation proposals but not the auditor ratification.
- Review the definitive proxy statement (Schedule 14A filed April 26, 2023) for detailed biographies of the elected directors and the rationale behind the compensation advisory vote.